Recombinant Human CD19 Protein, His-tagged, FITC conjugated
Cat.No. : | CD19-3309HF |
Product Overview : | FITC conjugated recombinant human CD19 (P15391) extracellular domain (Met 1-Lys 291), fused with a polyhistidine tag at the C-terminus, was produced in Human Cell. |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
Source : | HEK293 |
Species : | Human |
Tag : | His |
Form : | Lyophilized |
Molecular Mass : | The recombinant human CD19 consists of 283 amino acids and predictes a molecular mass of 31.6 kDa. In SDS-PAGE under reducing conditions, rhCD19 migrates as an approximately 47 kDa band due to glycosylation. |
Protein length : | 283 |
Endotoxin : | < 1.0 EU/ μg of the protein as determined by the LAL method. |
Characteristic : | Disulfide-linked homodimer Labeled with FITC via amines Excitation source: 488 nm spectral line, argon-ion laser Excitation Wavelength: 488 nm Emission Wavelength: 535 nm |
Stability : | Samples are stable for up to 12 months from date of receipt at -70 centigrade. |
Storage : | Store it under sterile conditions at -20 to -70 centigrade. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Storage Buffer : | Lyophilized from sterile PBS, pH 7.4 |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4 centigrade before opening to recover the entire contents. |
Gene Name : | CD19 CD19 molecule [ Homo sapiens ] |
Official Symbol : | CD19 |
Gene ID : | 930 |
mRNA Refseq : | NM_001178098 |
Protein Refseq : | NP_001171569 |
MIM : | 107265 |
UniProt ID : | P15391 |
Products Types
◆ Lysates | ||
CD19-2164MCL | Recombinant Mouse CD19 cell lysate | +Inquiry |
CD19-2005HCL | Recombinant Human CD19 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Q&As
- Reviews
Q&As (5)
Ask a questionCAR-T cells are engineered to express a receptor that recognizes CD19 on the surface of cancerous B cells. When they encounter these cells, they destroy them.
CD19 deficiencies can lead to primary immunodeficiencies, making individuals more susceptible to infections.
Side effects may include cytokine release syndrome (CRS), neurologic toxicity, and long-term B-cell aplasia.
CAR-T cell therapy is used to treat B-cell malignancies such as acute lymphoblastic leukemia (ALL) and certain types of non-Hodgkin lymphoma.
CAR-T cell therapy has shown remarkable effectiveness in inducing remissions in patients with CD19-positive malignancies, particularly in those who have relapsed or failed conventional treatments.
Customer Reviews (3)
Write a reviewThe manufacturer of CD19 protein has consistently provided outstanding technical support that has surpassed my expectations.
This protein demonstrates remarkable purity, stability, and specificity, ensuring utmost accuracy and reproducibility in my research endeavors.
Their dedication to customer satisfaction has been instrumental in overcoming obstacles and achieving successful results in my experiments.
Ask a Question for All CD19 Products
Required fields are marked with *
My Review for All CD19 Products
Required fields are marked with *
Inquiry Basket